On one hand, we speculate that estimating kidney function at dementia screening visits may help in risk stratification, provision of lifestyle recommendations, and perhaps consideration of cholinesterase inhibitors over other antidementia medications, given their potential kidney function–sparing effect.54 On the other hand, because awareness of CKD is still very low among patients and physicians,30 such testing may allow early identification of CKD cases who can benefit from nephrologist referral and initiation of antiproteinuric therapies (i.e., renin-angiotensin system inhibitors). The gene discussed is BCHE; the disease is chronic kidney disease.